Key Factor Supporting Cancer Cachexia Market Development in 2025: Impact Of Cancer Prevalence On The Cancer Cachexia Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Cancer Cachexia Market Size By 2025?
In recent years, there has been a substantial increase in the market size of cancer cachexia. This market is projected to escalate from a size worthy of $2.47 billion in 2024 to a value of $2.62 billion in 2025, marking a compound annual growth rate (CAGR) of 6.4%. Several factors fostered this surge in the historic period, including an enhanced comprehension of cancer biology, high cancer incidence rates, a burgeoning elderly population, an intensified emphasis on patient-focused care, widening therapy alternatives, and increasing cognizance amongst healthcare practitioners.

How Big Is the Cancer Cachexia Market Size Expected to Grow by 2029?
The market for cancer cachexia is predicted to expand significantly in the upcoming years, reaching a value of $3.33 billion in 2029, with a compound annual growth rate (CAGR) of 6.2%. This surge during the forecast period is primarily due to the heightened awareness around the management of cachexia, a larger aging population, the adoption of innovative therapeutic methodologies, increased spending on healthcare, and beneficial government initiatives. The forecast period is also expected to see major trends like heightened research and development activities, an expansion in therapeutic alternatives, better rates of diagnosis, breakthroughs in treatment modalities, and advancements in methods of supportive care.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-cachexia-global-market-report

Which Key Market Drivers Powering Cancer Cachexia Market Expansion and Growth?
The growth of the cancer cachexia market is set to increase in tandem with the rising prevalence of cancer. Cancer is a disease characterized by the uncontrolled growth and multiplication of abnormal cells, leading to the formation of tumors and interference with normal bodily functions. The emergence of cancer is linked to several aspects, such as changes in lifestyle, environmental influences, an aging populace, genetic inclinations, advanced diagnostic methods leading to early detection, and increased awareness which encourages more individuals to seek medical help. Medical technology advancements and heightened understanding of cancer and its associated complications are leading to more frequent cancer cachexia diagnoses and reports. Health care professionals are getting better at spotting the symptoms of cachexia, enabling them to intervene and start treatment sooner. For example, in December 2023, the Australian Bureau of Statistics, a government statistical organization in Australia, revealed that approximately 1.8% of the population or 456,200 people were diagnosed with cancer in 2022. On a similar note, in May 2024, the National Cancer Institute, a federal government agency in the United States, predicted that 2,001,140 new patients in the U.S. would be diagnosed with cancer in 2024, leading to an estimated 611,720 deaths. Worldwide, in 2022, there were nearly 20 million new cases coupled with 9.7 million fatalities related to cancer. Forecasts suggest that by 2040, new cancer cases will annually grow to 29.9 million, leading to an estimated 15.3 million cancer-related deaths. Hence, the rising incidence of cancer is fueling the expansion of the cancer cachexia market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15527&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Cancer Cachexia Market?
Top-tier companies in the cancer cachexia market are focusing on the creation of ground-breaking drugs, such as monoclonal antibodies for cachexia. The end goal is to design a specific treatment for cancer cachexia that boosts body mass, muscle volume, and enhances the overall life quality of the patients it afflicts. Cachexia monoclonal antibodies aim to combat the factors contributing to muscle and weight reduction. For example, Pfizer Inc., a pharmaceutical company based in the United States, disclosed positive data from its Phase 2 trial of Ponsegromab, an antibody focused on the GDF-15 agent, in patients with cancer cachexia. This occurred in September 2024. The trial revealed a notable rise in body weight, advanced muscle volume, appetite and physical activity, with the most potent outcomes from the 400 mg dose. Given these encouraging results, Pfizer is planning to commence definitive registration-focused studies in 2025 to delve deeper into Ponsegromab's potential as a treatment for cancer cachexia.

What Are the Emerging Segments in the Cancer Cachexia Market?
The cancer cachexia market covered in this report is segmented -

1) By Therapeutics: Progestogens, Corticosteroids, Combination Therapies, Other Therapeutics
2) By Mechanism Of Action: Appetite Stimulators, Weight Loss Stabilizers, Other Mechanisms Of Actions
3) By Distribution Channel: Hospital Stores, Retail Pharmacy Stores, Online Pharmacies

Subsegments:
1) By Progestogens: Megestrol Acetate, Medroxyprogesterone Acetate, Hydroxyprogesterone Caproate
2) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone
3) By Combination Therapies: Progestogens + Corticosteroids, Progestogens + Anabolic Agents, Corticosteroids + Anabolic Agents
4) By Other Therapeutics: Anabolic Agents, Appetite Stimulants, Anti-inflammatory Drugs, Nutritional Supplements

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15527&type=smp

Who Are the Global Leaders in the Cancer Cachexia Market?
Major companies operating in the cancer cachexia market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, Aspen Pharmacare Holdings Limited, Lupin Limited, Mallinckrodt plc, Akorn Inc., Aeterna Zentaris, XBiotech Inc.

Which are the Top Profitable Regional Markets for the Cancer Cachexia Industry?
North America was the largest region in the cancer cachexia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer cachexia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15527

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.